Adenoid Cystic Carcinoma Clinical Trial
Official title:
68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma
NCT number | NCT03319641 |
Other study ID # | 104902 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 25, 2017 |
Est. completion date | May 14, 2018 |
Verified date | May 2018 |
Source | Radboud University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy
Status | Completed |
Enrollment | 25 |
Est. completion date | May 14, 2018 |
Est. primary completion date | May 14, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - locally advanced, recurrent or metastatic ACC/SDC - Age = 18 years old - Ability to provide written informed consent Exclusion Criteria: - Contra-indication for PET imaging - Pregnancy - Breast feeding - Severe claustrophobia - Impaired renal function: MDRD <30 ml/min/1,73 m2 - Impaired liver function: AST and ALT = 2.5 x ULN (=5 x ULN for patients with liver metastases) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboudumc | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University | Adenoid Cystic Carcinoma Research Foundation |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | uptake of 68Ga-PSMA in ACC and SDC | To evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans | 0 days | |
Secondary | SUV of 68Ga-PSMA in ACC/SDC tumors | SUV of 68Ga-PSMA in ACC/SDC tumors | 0 days | |
Secondary | SUV of 68Ga-PSMA in the background | in order to calculate the SUV tumor to background ratio | 0 days | |
Secondary | correlation of SUV and IHC PSMA-staining | Correlate the tumor uptake (SUV) to the degree of immunohistochemical PSMA expression of the primary tumor on archival tissue | 0 days | |
Secondary | new metastases | To establish whether new metastatic lesions are found by 68GA-PSMA-PET/CT imaging | 0 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04973683 -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
|
Phase 1 | |
Completed |
NCT01417143 -
Dovitinib in Adenoid Cystic Carcinoma
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Recruiting |
NCT04801264 -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
|
Early Phase 1 | |
Recruiting |
NCT02942693 -
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT00581360 -
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT05553782 -
Drug Screening Using Novel IMD in ACC and Salivary Cancers
|
Early Phase 1 | |
Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02775370 -
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02780310 -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT04119453 -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
|
Phase 2 | |
Active, not recruiting |
NCT02098538 -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01524692 -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01558661 -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06462183 -
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
|
Phase 1 | |
Recruiting |
NCT01192087 -
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Recruiting |
NCT05774899 -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
|
Phase 1/Phase 2 |